Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance

Adaptive Biotechnologies CorpTrade
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.07 (market cap $4.04B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.61. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.

ADPTQDTY
Market Cap
$4.04B
Sector
HealthIncome / Options Overlay
52-Week High
$25.45$46.71
52-Week Low
$12.30$36.57
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.

Read more on QDTY